Viva Biotech Holdings
Viva Biotech Holdings
Your view on VBIZF
Overview
What the company does, where it operates, and who runs it.
About Viva Biotech Holdings
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Chen Cheney Mao
- Headquarters
- No.735, Ziping Road, Shanghai, CN
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Chen Cheney Mao
- Headquarters
- No.735, Ziping Road, Shanghai, CN
Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide.
The company provides discovery biology services, include protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody drug research and development services, include antigen preparation, multi-species discovery, monoclonal antibodies, antibodies functional screening and identification, antibody engineering transformation, antibody characteristics, and antibody cell line engineering transformation, as well as offers technology platforms, such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high throughput sequencing, computer-aided drug design, HDX-MS, crystal structure determination of protein, and SPR technology.
It also provides cell lines, crystal structures, GPCR proteins, antibodies, and proteins. In addition, the company offers contract development and manufacturing services for small molecule active pharmaceutical ingredients (APIs) and intermediates; and trades in APIs, intermediates, and formulations, as well as equity for service.
Further, it provides research service; laboratory rental services; and project management and bidding services, as well as sells compounds. The company was incorporated in 2008 and is headquartered in Shanghai, China.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Viva Biotech Holdings, and the rating behind it. VBIZF last traded at $0.34, 13.3× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Viva Biotech Holdings. Starting points for Viva Biotech Holdings: P/E 13.3, EPS $0.08, beta 1.72 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Viva Biotech Holdings. Viva Biotech Holdings does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Viva Biotech Holdings. Trailing twelve-month EPS for Viva Biotech Holdings stands at $0.08. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Viva Biotech Holdings. Viva Biotech Holdings has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Viva Biotech Holdings valued side by side against its closest peers. Viva Biotech Holdings is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Viva Biotech Holdings, and how their positions are changing. At a $724.5M market value, institutional positions materially move Viva Biotech Holdings's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Viva Biotech Holdings executives and directors. Shares of Viva Biotech Holdings have traded between $0.13 and $0.43 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Viva Biotech Holdings. Viva Biotech Holdings is a $724.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Viva Biotech Holdings. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Viva Biotech Holdings. Coverage tracks Viva Biotech Holdings within Biotechnology (Healthcare). Press releases and market coverage, newest first.